Please use this identifier to cite or link to this item:
|Title:||Platelet aggregation and exogenous factors from animal sources|
|Authors:||Manjunatha Kini, R.|
Platelet aggregation inducers
Platelet aggregation inhibitors
|Source:||Manjunatha Kini, R. (2004-12). Platelet aggregation and exogenous factors from animal sources. Current Drug Targets - Cardiovascular and Haematological Disorders 4 (4) : 301-325. ScholarBank@NUS Repository. https://doi.org/10.2174/1568006043335835|
|Abstract:||Platelet aggregation plays a crucial role in thrombosis. This review describes exogenous factors isolated from various animal sources, including venoms and the salivary glands that interfere in platelet aggregation. Some of these factors induce platelet aggregation or agglutination, whereas others inhibit platelet aggregation. These proteins range from small molecular weight peptides to large proteins. Some of these proteins exhibit various enzymatic activities, while others are nonenzymatic. These exogenous factors affect platelet aggregation by various mechanisms and thus they have been classified based on their mechanism of action. Many of these proteins have evolved through both convergent and divergent evolution. For example, platelet aggregation inhibitors, which interfere in the interactions between fibrinogen and its receptor, the glycoprotein IIb/IIIa complex, show extreme structural diversity but they share the common functional site of Arg-Gly-Asp (RGD) tripeptide segment. On the other hand, C-type lectin related proteins exhibit diverse biological effects by interacting with different proteins, but share common structural scaffold. Thus the mechanistic and structure-function studies of these exogenous proteins have contributed significantly to the understanding of molecular mechanisms of platelet aggregation and to the development of potent antiplatelet agents, respectively. A number of new exogenous factors have been identified recently and the search is still on for novel factors that interfere with platelet aggregation. Further studies in this area will help in the development of novel strategies for treating cardiovascular and hematological disorders. © 2004 Bentham Science Publishers Ltd.|
|Source Title:||Current Drug Targets - Cardiovascular and Haematological Disorders|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 8, 2018
checked on Mar 10, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.